Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8899 results

  1. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development Reference number: GID-HST10022 Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  4. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development Reference number: GID-TA10024 Expected publication date:  28 June 2017

    Technology appraisal guidance
    In development

  6. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    In development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

    NICE guideline
    In development

  9. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  12. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    Health technology evaluations
    In development

  13. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

    Health technology evaluations
    In development

  15. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development